Trial Profile
A Phase II Study on treatment for Ph+ Acute Lymphoblastic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Antineoplastics
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 01 Mar 2019 Results published in the Annals of Hematology
- 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as result presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 06 Sep 2012 New trial record